金城医药：子公司注射用头孢地嗪钠通过仿制药一致性评价

Group 1 - The core point of the article is that Jincheng Pharmaceutical (300233) announced that its subsidiary, Jincheng Jinsu, received approval from the National Medical Products Administration for the supplementary application of injectable Cefodizime Sodium (0.5g, 1.0g), which has passed the consistency evaluation of quality and efficacy for generic drugs [1] - Injectable Cefodizime Sodium is a third-generation cephalosporin primarily used for infections caused by sensitive bacteria such as Streptococcus and Pneumococcus [1] - According to the data from the China Pharmaceutical Market, the sales revenue of injectable Cefodizime Sodium in public medical institutions in China is projected to be 1.074 billion RMB in 2022, 675 million RMB in 2023, and 394 million RMB in 2024 [1]